Page last updated: 2024-09-03

vadimezan and Adenoma, Prolactin-Secreting, Pituitary

vadimezan has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Griffiths, JR; Howe, FA; McIntyre, DJ; McPhail, LD; Robinson, SP1
Griffiths, JR; Kelland, LR; Kestell, P; Ludwig, C; McIntyre, DJ; McPhail, LD; Robinson, SP1

Other Studies

2 other study(ies) available for vadimezan and Adenoma, Prolactin-Secreting, Pituitary

ArticleYear
Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.
    International journal of radiation oncology, biology, physics, 2008, Aug-01, Volume: 71, Issue:5

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Blood Volume; Blood Volume Determination; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organ Size; Oxides; Prolactinoma; Rats; Rats, Inbred WF; Regional Blood Flow; Xanthones

2008
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
    Neoplasia (New York, N.Y.), 2006, Volume: 8, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Biomarkers; Capillary Permeability; Cell Line, Tumor; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactinoma; Rats; Rats, Inbred WF; Subcutaneous Tissue; Xanthones

2006